St. Jude launches chronic pain neurostim Axium in U.S.

St. Jude Medical ($STJ) has launched its Axium Neurostimulator System for dorsal root ganglion (DRG) stimulation to treat patients with chronic pain. The device was approved by the FDA in February. It's intended for use by patients who have uncontrolled pain using traditional spinal cord stimulation (SCS). A pivotal trial found that Axium DRG stimulation provided superior pain relief to traditional tonic SCS. More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.